Meeting Mic

In this episode of Meeting Mic, we bring you pearls and perspectives from the Association of Vision and Research in Ophthalmology 2026. Jason Greenfield, MD, MBA, Alon Harris, MS, PhD, FARVO, and Yash Lahoti spoke with Healio about their study, which was designed to look at some of the unknown risk factors for glaucoma. 00:37 Next, Michael Zhu, a medical student at Duke University School of Medicine, told Healio about his presentation about retina imaging and how it may reveal links to Parkinson's disease. 06:12 And, Iris Fang-Yu Hu, MD, discusses her presentation on how using visual prompts helped improve glaucoma detection by a large language model. 08:35 Top headlines from the meetings. 09:31 Read the full coverage here: Glaucoma, hypertension may be linked to dementia risk Source: Greenfield J, et al. Artificial intelligence ready and exploratory atlas for diabetes insights: The association between glaucoma, hypertension, and cognitive performance. Presented at: Association for Research in Vision and Ophthalmology meeting; May 3-7, 2026; Denver. Imaging reveals link between inner nuclear layer thickness, Parkinson's disease Source: Zhu M, et al. Macular retinal layer thickness in early Parkinson's disease. Presented at: Association for Research in Vision and Ophthalmology meeting; May 3-7, 2026; Denver. Reference images help AI model detect glaucoma Source: Hu I, et al. Providing reference images to LLMs improves glaucoma detection from fundus photos. Presented at: Association for Research in Vision and Ophthalmology meeting; May 3-7, 2026; Denver. Smoking may be modifiable risk factor for myopia-related vision loss Source: Flitcroft I, et al. Smoke gets in your eyes: Evidence that smoking is the first modifiable risk factor for myopia-related vision impairment. Presented at: Association for Research in Vision and Ophthalmology meeting; May 3-7, 2026; Denver. Thyroid eye disease shows long-term progression in real-world dataset Source: Ramesh S, et al. Disease progression in thyroid eye disease: Findings from a large real-world study in the United States. Presented at: Association for Research in Vision and Ophthalmology meeting; May 3-7, 2026; Denver.

In this episode of Meeting Mic, we bring you pearls and perspectives from the American Academy of Neurology (AAN) Annual Meeting 2026. Christopher Lock, MD, discusses key takeaways from the meeting. 00:12 Claire Delpirou Nouh, MD, highlights the meeting's major discussions and presentations. 05:27 Top headlines from the meetings. 08:42 Read the full coverage here: Improved mortality outweighs cognitive risks in GLP-1 analog use Source: Thorman IB, et al. Long-term risk of cognitive impairment with GLP-1 analogues in older adults with type 2 diabetes mellitus. Presented at: American Academy of Neurology Annual Meeting; April 5-9, 2025; San Diego. Prolonged seizures negatively impact productivity, quality of life in patients, caregivers Source: Trinka E, et al. Loss of productivity, seizure worry, and patient and caregiver quality of life associated with prolonged seizures: Results from a global real-world point-in-time study. Presented at: American Academy of Neurology Annual Meeting; April 18-22, 2026; Chicago. Improvements in biological age linked to lower stroke risk, healthier brains Source: Rivier C, et al. Improvements in biological age acceleration lead to better neuroimaging, clinical and cognitive markers of brain health. Presented at: American Academy of Neurology Annual Meeting; April 5-9, 2025; San Diego.

In this episode of Meeting Mic, we bring you pearls and perspectives from Miami Breast Cancer Conference 2026. Paolo Tarantino, MD, PhD, discusses key takeaways from the meeting. :19 Paolo Tarantino, MD, PhD, highlights the meeting's major discussions and presentations. 3:02 Hope S. Rugo, MD, provides an overview of the inspiring and revelatory information presented at the conference. 4:41 Read the full coverage here: https://www.healio.com/news/hematology-oncology/20260317/video-oncology-education-key-to-understanding-growing-data-in-breast-cancer-treatment https://www.healio.com/news/hematology-oncology/20260317/video-discussions-on-her2positive-breast-cancer-treatment-may-alter-way-of-practicing  https://www.healio.com/news/hematology-oncology/20260317/video-trastuzumab-deruxtecan-in-adjuvant-setting-may-be-preferred-in-breast-cancer https://www.healio.com/news/hematology-oncology/20260325/video-breast-cancer-conference-fuses-data-specialties-in-continuum-of-patient-care https://www.healio.com/news/hematology-oncology/20260325/video-keynote-speaker-inspires-others-to-push-beyond-the-barriers-in-breast-cancer

In this episode of Meeting Mic, we bring you the highlights and insights from the San Antonio Breast Cancer Symposium 2025, as well as Healio's top headlines from the meeting. Amy Comander, MD, DipABLM, FACLM, MSCP, highlights presentations at this year's meeting. :26 Jun J. Mao, MD, MSCE, discusses results from a phase 2 trial surrounding acupuncture for breast cancer. 1:50 Amanda M. Woodworth, MD, FACS, CPE, describes a digital toolkit for advancing risk-informed breast cancer screening. 4:41 Read the full coverage here: Advancements in Breast Cancer, Lifestyle Medicine and A Preview of SABCS with Amy Comander, MD Sentinel node biopsy pioneer to receive William L. McGuire Memorial Lecture Award Tucatinib regimen delays disease progression in advanced HER2-positive breast cancer Disclosures: Comander reports no relevant financial disclosures. Healio could not confirm financial disclosures for Mao and Woodworth at the time of publishing.

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2025 Neuroscience Educational Institute (NEI) Annual Congress. David W. Goodman, MD, LFAPA, discusses his presentation about ADHD in adults including diagnosis, treatment and the current challenges. :22 Katherine Dahlsgaard, PhD, ABPP, talks about her presentations on behavioral interventions for sleepy adolescents as well as the challenges physicians face in prescribing psychiatric medicines. 5:43 Kari L. Franson, PharmD, PhD, BCPP, FNAP, highlights her presentations on the current status of prescription digital therapeutics and the practice of de-prescribing psychiatric medicines.  17:28 Disclosures: Goodman reports receiving honoraria from Clinical Care Options, HCPLive, Medscape, Neuroscience Education Institute and World Federation for ADHD. Healio was unable to confirm relevant disclosures for Dahlsgaard or Franson at the time of publication.

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2025 Gerontological Advanced Practice Nurses Association (GAPNA) Annual Conference. Kimberly Posey, AGPCNP-BC, DNP, PhD, GS-C, discusses the purpose for the meeting, and highlights from this year's conference. :19 George Peraza-Smith, DNP, A-GNP-C, GNP-BC, GS-C, CNE, FAANP, immediate past president of GAPNA, provides an overview on popular presentations from the meeting, and goals for the future of the organization. 12:25 Disclosures: Healio was unable to confirm relevant disclosures at the time of publication.

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2025 American Society of Retina Specialists annual meeting, as well as Healio's top headlines from the meeting. Andrew G. Lee, MD, discusses when retina experts should refer patients to a neuro-ophthalmologist. 0:29 Sunir J. Garg, MD, FACS, FASRS, provides an overview of lessons learned from two complex surgical cases. 1:52 Sunir J. Garg, MD, FACS, FASRS, overviewed key findings from the Global Trends in Retina Survey. 5:16 Michael O'Rouke talks collaborating with Boehringer Ingelheim to develop extended-release therapies for ophthalmic diseases. 8:17 Jay S. Duker, MD, discusses EyePoint Pharmaceuticals' second phase 3 trial of Duravyu in patients with wet age-related macular degeneration. 11:08 Read the full coverage here: https://www.healio.com/news/ophthalmology/20250731/andrew-g-lee-shares-neuroophthalmology-advice-for-retina-specialists https://www.healio.com/news/ophthalmology/20250731/sunir-garg-shares-solutions-to-complex-surgical-cases https://www.healio.com/news/ophthalmology/20250730/revana-collaborates-with-boehringer-ingelheim-to-develop-extendedrelease-therapies https://www.healio.com/news/ophthalmology/20250807/eyepoint-completes-enrollment-in-second-phase-3-trial-of-sustainedrelease-amd-therapy https://www.healio.com/news/ophthalmology/20250811/survey-treatment-for-recalcitrant-diabetic-macular-edema-varies-between-us-europe Long-term benefits seen with Gore-Tex sutures for scleral fixation of IOLs Source: Acaba-Berrocal L, et al. Long-term outcomes of pars plana vitrectomy and polytetrafluoroethylene sutured scleral-fixated intraocular lenses. Presented at: American Society of Retina Specialists annual meeting; July 30-Aug. 2, 2025; Long Beach, California. Study supports Iluvien as 'long-acting option' in diabetic macular edema Source: Singer MA, et al. NEW DAY: Study design, study sites, patient enrollment: A study of intravitreal Iluvien (fluocinolone acetonide) implant as baseline therapy in patients with early diabetic macular edema (DME) (NEW DAY). Presented at: American Society of Retina Specialists annual meeting; July 30-Aug. 2, 2025; Long Beach, California. Disclosures: Duker reports being president and CEO of EyePoint Pharmaceuticals. Garg reports no relevant financial disclosures. Lee reports no relevant financial disclosures. O'Rourke reports being CEO of Re-Vana Therapeutics.

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2025 ASCO Annual Meeting, as well as Healio's top headlines from the meeting. Chinmay Jani, MD, discusses findings highlighting how alcohol-related cancer mortality has risen sharply over the past few decades. :19 Rachel I. Vogel, PhD, provides and overview on factors contributing to the time burden cancer care places on patients. 3:02 Alexander D. Sherry, MD, discusses how improvements in OS or quality of life after phase 3 oncology trials are based on improvements in unvalidated alternative endpoints. 4:41 Lucas A. Mavromatis, ScB, discusses findings on how GLP-1 receptor agonists may reduce risk for obesity-related cancers among people with diabetes. 7:20 Sonali M. Smith, MD, talks with Oncology Overdrive host Shikha Jain, MD, about presentations on lymphoma at this year's ASCO meeting. 9:57 Read the full coverage here: https://www.healio.com/news/hematology-oncology/20250531/study-reveals-shocking-rise-in-alcoholrelated-cancer-deaths https://www.healio.com/news/hematology-oncology/20250603/time-burden-people-with-cancer-face-often-vastly-underestimated https://www.healio.com/news/hematology-oncology/20250604/few-phase-3-oncology-trials-demonstrate-improvements-in-os-quality-of-life https://www.healio.com/news/hematology-oncology/20250522/glp1-receptor-agonists-confer-modest-protection-against-obesityrelated-cancers https://www.healio.com/news/hematology-oncology/podcasts/oncology-overdrive/episode-119 Exercise described as 'novel, first-in-class' colon cancer therapy Source: Booth CM, et al. Abstract LBA3510. Presented at: ASCO Annual Meeting; May 30-June 3, 2025; Chicago. At-home intervention has potential to enhance cancer care delivery, outcomes Source: Nipp RD, et al. Abstract 11003. Presented at: ASCO Annual Meeting; May 30-June 3, 2025; Chicago. Disclosures: Jani reports no relevant financial disclosures. Mavromatis reports no relevant financial disclosures. Sherry reports honoraria from Sermo.  Smith reports no relevant financial disclosures. Vogel reports a consulting/advisory role with Voluntis.

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2025 American Academy of Neurology Annual Meeting. Mary A. O'Neal, MD, FAAN, and Ratna K. Bhavaraju-Sanka, MD, FAAN, discuss their efforts to address the lack of access to neurological care by partnering with primary care. :34 Merit E. Cudkowicz, MD, MSc, FAAN, speaks with Healio about being honored The American Academy of Neurology's Lifetime Achievement Award for her extensive work in ALS research. 2:50 Read the full coverage here: https://www.healio.com/news/neurology/20250417/partners-in-crime-neurologists-collaborate-with-pcps-to-improve-brain-health https://www.healio.com/news/neurology/20250407/merit-e-cudkowicz-md-msc-receives-lifetime-award-for-als-research-im-not-done-yet ACCORD-2: AXS-05 delays relapse time to Alzheimer's disease agitation Source: Grossberg G, et al. Efficacy and safety of AXS-05 in Alzheimer's disease agitation: Results from ACCORD-2, a phase 3 randomized withdrawal double-blind placebo-controlled study. Presented at: American Academy of Neurology Annual Meeting; April 5-9, 2025; San Diego. Risk for ARIA driven by patient genotype, presence of hemorrhage in early Alzheimer's Source: Biffi A, et al. ARIA insights from the donanemab trials: Amyloid-targeted therapy in early symptomatic Alzheimer's disease. Presented at: American Academy of Neurology Annual Meeting; April 5-9, 2025; San Diego. Microplastics in oceans may increase disability risk among coastal populations Source: Ganatra S, et al. Marine microplastics levels and the prevalence of neurologic disability. Presented at: American Academy of Neurology Annual Meeting; April 5-9, 2025; San Diego. Nightmares may increase risk for early death Source: Otaiku A, et al. Distressing dreams and risk of premature mortality: A population-based multicohort study. Presented at: American Academy of Neurology Annual Meeting; April 5-9, 2025; San Diego. Disclosures: Bhavaraju-Sanka reports serving as a consultant for Amgen and Argenx. Cudkowicz reports financial relationships with AB Science, AC Immune SA, Aclipse, Annals of Neurology, Biogen, Coya Therapeutics, Cytokinetics, Eli Lilly, Immunity Pharma, InFlectis, Locust Walk, Novartis, Ono Pharmaceutical, Otsuka Pharmaceutical, Pasithea Therapeutics, Pontifax, Praxis Precision Medicine, Transposon, QurAlis, Regeneron, VectorY. She also reports receiving publishing royalties from a publication relating to health care. Her institution(s) received support from ALS Finding a Cure, ALS ONE, Biohaven, Calico, Clene Nanomedicine, Denali, ITB, Johnson & Johnson, the National Institute of Neurological Disorders and Stroke, PharmAust, Prilenia, Seelos, UCB/RA and Woolsley. O'Neal reports serving as a consultant and excerpt witness for Circo; being an employee of Best Doctors; and receiving publishing royalties from a health care-related publication.

In this episode of Meeting Mic, we bring you expert insights from the ASH Annual Meeting and Exhibition with a focus on leukemia, as well as Healio's top headlines from the meeting. Aaron T. Gerds, MD, MS, discusses how socioeconomic disparities affect access to allogeneic hematopoietic stem cell transplantation for people with acute myeloid leukemia. :24 Hua Zhang, MD, PhD, reviews findings of bicistronic chimeric antigen receptor T-cell therapy induced durable response for most children with relapsed or refractory B-lineage acute lymphoblastic leukemia. 6:29 Moath Albliwi, MD, discusses the results of a study he co-presented examining treatment of elderly patients with acute myeloid leukemia. 00:00 Alexey Danilov, MD, PhD, reviews the efficacy of epcoritamab among heavily pretreated patients with advanced chronic lymphocytic leukemia. 00:00 Lee Greenberger, PhD, discusses results of the AMPLIFY study. 16:30 Read the full coverage here: Socioeconomic factors a barrier to HSCT for people with acute myeloid leukemia Bicistronic CAR-T effective for children with relapsed B-ALL VIDEO: Study probes treatment of elderly patients with acute myeloid leukemia First-line regimen improves PFS in chronic lymphocytic leukemia Epcoritamab exhibits 'very encouraging' efficacy in heavily pretreated CLL Addition of blinatumomab to chemotherapy improves outcomes for children with B-cell ALL Disclosures: Albliwi reports no relevant financial disclosures. Danilov reports research funding from and/or consulting roles with AbbVie, AstraZeneca, Bayer, Bristol Myers Squibb, Genentech, Genmab, Incyte, Janssen and other companies. Please see the abstract for all other researchers' relevant financial disclosures. Gerds reports consulting roles with AbbVie, Bristol Myers Squibb, Disc Medicine, GSK, PharmaEssentia and Rain Oncology. Please see the abstract for all other researchers' relevant financial disclosures. Greenberger reports no relevant financial disclosures. Rau reports consulting/advisory roles with and/or honoraria from Jazz Pharmaceuticals and Servier. She also reports her spouse is employed by AbbVie. Please see the abstract for all other researchers' relevant financial disclosures. Zhang reports no relevant financial disclosures.

In this episode of Meeting Mic, we bring you the highlights and insights from the San Antonio Breast Cancer Symposium 2024, as well as Healio's top headlines from the meeting. Judy Garber, MD, MPH, chief of the division of cancer genetics and prevention at Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School, reviews results of the OlympiA trial. :25 Raza Hoda, MD, a pathologist at Cleveland Clinic and assistant professor of pathology at Cleveland Clinic Lerner College of Medicine, discusses results from the DESTINY-Breast04 and DESTINY-Breast06 trials. 1:55 Shimoli Barot, MD, medical oncologist at Cleveland Clinic Cancer Institute, examines the results of a study observing exceptional treatment response in patients with metastatic breast cancer. 6:02 Eleonora Teplinsky further discusses results of the COMET trial. 10:38 Jennifer A. Ligibel discusses an overview analysis looking at the relationship between body mass index at the time of breast cancer diagnosis and distant recurrence. 19:27 Read the full coverage here: VIDEO: OlympiA trial shows 'continued benefit' in breast cancer survival VIDEO: Study investigates HER2-low, ultralow eligibility for trastuzumab deruxtecan VIDEO: Study investigates exceptional treatment response in metastatic breast cancer Active monitoring safe for some patients with low-risk ductal carcinoma in situ Source: Hwang ES, et al. Abstract GS2-05. Presented at: San Antonio Breast Cancer Symposium; Dec. 10-13, 2024; San Antonio. Terminated study's 'challenges' may guide future trials of MRD-guided breast cancer therapy Source: Turner N, et al. Abstract GS3-01. Presented at: San Antonio Breast Cancer Symposium; Dec. 10-13, 2024; San Antonio. Obesity elevates risk for distant recurrence, mortality in early-stage breast cancer Source: Pan H, et al. Abstract GS2-09. Presented at: San Antonio Breast Cancer Symposium; Dec. 10-13, 2024; San Antonio. Disclosures: Barot reports no relevant financial disclosures. Garber reports no relevant financial disclosures. Hoda reports no relevant financial disclosures. Teplinsky reports no relevant financial disclosures.

In this episode of Meeting Mic, we bring you expert insights from the ASH Annual Meeting and Exhibition, as well as Healio's top headlines from the meeting. Gwen L. Nichols, MD, reviews a panel discussion on how hematologists and oncologists can best address patients' concerns as AI's role in medicine invariably expands. :24 Thomas G. Knight, MD, addresses financial toxicity for people with blood cancer. 6:29 Charles S. Abrams, MD, discusses results of the HIBISCUS trial and its implications for vaso-occlusive events. 16:30 Read the full coverage here: AI in hematology: 'The good, the bad and the ugly' Mitigating financial toxicity 'better than any drug' for people with cancer Etavopivat could offer 'great benefit' in sickle cell disease ASH recognizes Judith Kleinerman, MD, with Exemplary Service Award GLP-1s reduce thrombosis risk among people with diabetes, regardless of obesity Disclosures: Abrams reports he is chair of the ASH Research Collaborative's Sickle Cell Disease Clinical Trials Network Oversight Committee. Knight reports no relevant financial disclosures. Nichols reports no relevant financial disclosures.

In this episode of Meeting Mic, we bring you pearls and perspectives from the American Academy of Ophthalmology 2024 Meeting with a focus on AMD and retina. David A. Eichenbaum, MD, discusses results from a phase 1 trial investigating axitinib for the treatment of neovascular age-related macular degeneration. :28 Douglas Love discusses the company's phase 3 program in geographic atrophy. 2:37 Pravin U. Dugel, MD, discusses the next steps for the phase 3 SOL-1 and SOL-R studies. 3:54 Jeremiah Brown, MS, MD, presents results from the phase 4 Elevatum trial investigating faricimab for diabetic macular edema. 5:17 Read the full coverage here: https://www.healio.com/news/ophthalmology/20241024/video-axitinib-shows-clinically-meaningful-treatment-burden-reduction-in-wet-amd https://www.healio.com/news/ophthalmology/20241023/video-phase-3-geographic-atrophy-program-focuses-on-visual-acuity https://www.healio.com/news/ophthalmology/20241021/video-ocular-therapeutix-shares-update-on-phase-3-axpaxli-studies https://www.healio.com/news/ophthalmology/20241018/video-faricimab-shows-amazing-outcomes-in-underrepresented-patients-with-dme Teleretinal screening for diabetic retinopathy beneficial Source: Weng CY. The use of teleretinal screening for diabetic retinopathy. Presented at: American Academy of Ophthalmology meeting; Oct. 18-21, 2024; Chicago. Oral treatment aims to reduce GA progression by slowing vitamin A dimerization Source: Melamud A. Gildeuretinol in geographic atrophy: Results from SAGA, a 2-year, randomized, double-masked, placebo-controlled Study. Presented at: American Academy of Ophthalmology meeting; Oct. 18-21, 2024; Chicago. Fas inhibitor shows benefit in some cases of macula-off rhegmatogenous retinal detachment Source: Borkar DS. Fas inhibition with intravitreal ONL1204 for the treatment of macula-off rhegmatogenous retinal detachment: Results from a phase 2 study. Presented at: American Academy of Ophthalmology meeting; Oct. 18-21, 2024; Chicago. Disclosures: Brown reports being an investigator and speaker for Genentech and a researcher for EyeBio, Regeneron and Regenxbio. Dugel reports being executive chairman, president and CEO of Ocular Therapeutix. Eichenbaum reports being a consultant and investigator for Ocular Therapeutix. Love reports being president and CEO of Annexon Biosciences.

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2024 European Society for Medical Oncology Congress with a focus on leukemia. Douglas Tremblay, MD, highlights an abstract related to leukemia at the conference. :29 Douglas Tremblay, MD, discusses another abstract related to leukemia. 5:23 Noah M. Merin, MD, PhD, focuses on recent findings in AML, ALL and MDS presented at the Congress. 9:08 Rosalie Griffin, PhD, discusses her winning poster on biomarker testing in lymphoid malignancies. 12:57 Rosalie Griffin, PhD, also shares her thoughts on a presentation looking at point mutations in lymphoid malignancies. 17:13 Read the full coverage here: https://www.healio.com/news/hematology-oncology/20241009/video-new-car-tcell-product-may-reduce-side-effects-in-all https://www.healio.com/news/hematology-oncology/20241009/video-timdarpacept-examined-in-dedicated-chronic-myelomonocytic-leukemia-trial https://www.healio.com/news/hematology-oncology/20241009/video-no-association-between-point-mutations-and-blood-cancer-precursors https://www.healio.com/news/hematology-oncology/20241009/video-biomarkers-relationship-with-blood-cancers-examined-at-esmo Disclosures: Griffin reports no relevant financial disclosures. Tremblay reports contracted research funding paid to his institution from Cogent Biosciences, Gilead, Sobi and Sumitomo, and consulting fees from AbbVie, Cogent Biosciences, GSK, Novartis, Pharmaessentia, Sierra Oncology and Sobi. Healio could not confirm relevant financial disclosures for Merin at the time of posting.

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2024 World Conference on Lung Cancer, as well as Healio's top headlines from the meeting. Benjamin P. Levy, MD, discusses key takeaways from the meeting. 0:28 Read the full coverage here: Ivonescimab extends PFS vs. pembrolizumab in advanced NSCLC, may be 'a new standard' Source: Zhou C, et al. Abstract 2700. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego. Perioperative nivolumab improves outcomes in resectable NSCLC Source: Forde PM, et al. Abstract 3589. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego. Despite progress, barriers to lung cancer biomarker testing persist Source: Smeltzer M, et al. Abstract 3000. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego. Disclosures: Healio could not confirm relevant financial disclosures for Levy at the time of posting.

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2024 ASCO Annual Meeting, as well as Healio's top headlines from the meeting. Andrew Hantel, MD, discusses results of a study on racial disparities in acute myeloid leukemia trials. :27 Christine McMahon, MD,  discusses results of the phase 3 ASC4FIRST study, which examined asciminib versus tyrosine kinase inhibitors for patients with newly diagnosed chronic-phase CML. 3:30 Andrew Hantel, MD, discusses researching inequities in acute myeloid leukemia treatment in historically marginalized communities. 4:35 Christine McMahon, MD, presents results of a randomized trial of a care model for patients with acute myeloid leukemia and myelodysplastic syndrome. 7:09 Christine McMahon, MD, highlights the ACCESS study into post-transplant graft-versus-host disease, which produced "impressive" rates of post-transplant overall survival at 1 year. 10:22 Read the full coverage here: https://www.healio.com/news/hematology-oncology/20240625/video-a-patients-raceethnicity-affects-eligibility-for-acute-myeloid-leukemia-trials https://www.healio.com/news/hematology-oncology/20240620/video-strong-results-for-asciminib-in-chronic-myelogenous-leukemia https://www.healio.com/news/hematology-oncology/20240625/video-treatment-delays-do-not-lead-to-acute-myeloid-leukemia-survival-disparities https://www.healio.com/news/hematology-oncology/20240620/video-palliative-care-model-increases-quality-of-life-for-patients-with-leukemia https://www.healio.com/news/hematology-oncology/20240620/video-study-produces-impressive-posttransplant-graftversushost-disease-survival-rates Disclosures: Hantel reports no relevant financial disclosures. McMahon reports receiving institutional funding from Syndax and Syros and serving on a safety monitoring committee for Kura Oncology.

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2024 ASCO Annual Meeting with a focus on leukemia, as well as Healio's top headlines from the meeting. Jorge E. Cortes, MD, discusses how asciminib demonstrated superior efficacy to standard first-line therapies for certain patients with newly diagnosed chronic myeloid leukemia. :27 Oreofe O. Odejide, MD, MPH, highlights the importance of this study. 3:30 Read the full coverage here: https://www.healio.com/news/hematology-oncology/20240531/asciminib-may-transform-treatment-paradigm-for-chronic-myeloid-leukemia New approach 'redefining what is a suitable donor' for stem cell transplant Source: Al Malki MM, et al. Abstract 6503. Presented at: ASCO Annual Meeting; May 30 – June 4, 2024; Chicago. Disclosures: Cortes reports research funding to his institution from or consultant/advisory roles with Gilead Sciences, Jazz Pharmaceuticals, Novartis, Pfizer, Takeda and other companies.

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2024 ASCO Annual Meeting, as well as Healio's top headlines from the meeting. Joseph A. Greer, PhD, discusses how early palliative care via telehealth had an equivalent impact on quality of life as in-person visits for patients with advanced non-small cell lung cancer. :27 Charu Aggarwal, MD, MPH, FASCO, further discusses these findings during a press briefing. 3:30 Heinz-Josef Lenz, MD, shares his thoughts on the first-line immunotherapy combination of nivolumab and ipilimumab in colorectal cancer. 4:35 Fumiko Chino, MD, discusses findings on the need for a more effective and transparent prior authorization process to ensure patients receive timely access to essential pain management. 7:09 Suneel Kamath, MD, provides an overview of findings assessing how the microbiome profile of early-onset pancreatic adenocarcinoma is distinct from that of average-onset disease. 10:22 Julie R. Gralow, MD, FACP, FASCO, discusses the important implications of a prospective study on young breast cancer survivors who attempted pregnancy and became pregnant. 12:54      Read the full coverage here: https://www.healio.com/news/hematology-oncology/20240602/we-have-the-technology-telehealth-increases-access-to-palliative-care-for-cancer https://www.healio.com/news/hematology-oncology/20240602/practicechanging-data-support-firstline-immunotherapy-combination-in-colorectal-cancer https://www.healio.com/news/hematology-oncology/20240531/findings-highlight-need-to-improve-prior-authorization-process-for-cancer-pain-management https://www.healio.com/news/hematology-oncology/20240603/tumor-microbiome-profiles-in-pancreatic-cancer-differ-by-age-of-onset https://www.healio.com/news/hematology-oncology/20220611/intramuscular-recombinant-erwinia-asparaginase-active-safe-in-leukemia-lymphoma-subsets Glucose-lowering drugs reduce risk for obesity-related cancers Source: Lin CH, et al. Abstract 10508. Presented at: ASCO Annual Meeting; May 30 – June 4, 2024; Chicago. Chemotherapy regimen improves survival in advanced esophageal cancer Source: Hoeppner J, et al. Abstract LBA1. Presented at: ASCO Annual Meeting; May 31-June 4, 2024: Chicago. Disclosures: Chino reports no relevant financial disclosures. Greer reports a consulting role with BeiGene; research funding from Blue Note Therapeutics and NCCN/AstraZeneca; and royalties from Oxford University Press and Springer Publishing Company. Please see the abstract for all other researchers' relevant financial disclosures.[JJ1]  Kamath reports no relevant financial disclosures.  Lenz reports honoraria from, consulting/advisory roles with, or travel, accommodations or expenses from 3T Biosciences, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Fulgent Genetics, G1 Therapeutics, GSK, Isofol Medical, Jazz Pharmaceuticals, Merck Serono, Oncocyte and Roche. Please see the abstract for all other researchers' relevant financial disclosures.

In this episode of Meeting Mic, we bring you Healio's top headlines from ACR Convergence 2023.  Eric Roberts, PhD, MPH, compares the uptake of biosimilar infliximab among patients with Medicare, Medicaid and private insurance in the U.S. :19  Shivani Garg, MD, MS, discusses how a therapeutic range of hydroxychloroquine blood levels may reduce the odds of high lupus disease activity. 2:09  Kaleb Michaud, PhD, discusses patients with rheumatoid arthritis who reported having long COVID in the past year demonstrating "many symptoms" of long COVID prior to initial infection. 12:00  Leonard H. Calabrese, DO, highlights the "year in review", issues in vasculitis, and cautionary notes on CAR T cell therapies. 14:18   Jill Buyon, MD, discusses how pregnant patients with very low anti-Ro antibody titers of less than 1,000 units per mL have minimal-to-no risk for fetal atrioventricular block. 15:15  Read the full coverage here:  https://www.healio.com/news/rheumatology/20231113/medicare-fails-to-keep-up-with-medicaid-private-market-on-infliximab-biosimilar-uptake  https://www.healio.com/news/rheumatology/20231120/stay-within-hydroxychloroquine-therapeutic-threshold-to-reduce-active-lupus-flare-risk   https://www.healio.com/news/rheumatology/20231116/patients-with-rheumatoid-arthritis-report-many-symptoms-of-long-covid-prior-to-infection   @LCalabreseDO  https://www.healio.com/news/rheumatology/20231113/pregnant-patients-with-low-antiro-titers-have-little-to-no-risk-for-fetal-heart-block  Disclosures:  Roberts, Garg, Michaud and Calabrese report no relevant financial disclosures. Buyon reports financial disclosures with Bristol-Myers Squibb, GlaxoSmithKline and Related Sciences. 

In this episode of Meeting Mic, we bring you Healio's top headlines from ACG 2023. Paul Feuerstadt, MD, FACG, AGAF, discusses data that link health-related quality of life and microbiome composition among patients with recurrent Clostridioides difficile infection. :38 Edward V. Loftus Jr., MD, FACG, discusses results from the INSPIRE trial for ulcerative colitis. 7:52 Jan Wehkamp, MD, PhD, discusses results from the QUASAR study, in which Tremfya outperformed placebo in clinical response patients with ulcerative colitis. 12:08 Paul Feuerstadt also discusses the evolution of treatment for Clostridioides difficile infection, from antimicrobials to recently FDA-approved live biotherapeutics. 15:32 Thomas F. Imperiale, MD, discusses the results of the BLUE-C study, which evaluated the clinical performance of Cologuard, a next-generation, multitarget stool DNA test. 21:08 Read the full coverage here: https://www.healio.com/news/gastroenterology/20231023/video-rebyota-not-only-shuts-down-recurrence-also-affects-quality-of-life-in-c-diff https://www.healio.com/news/gastroenterology/20231025/video-risankizumab-a-great-option-for-patients-induces-clinical-remission-in-uc https://www.healio.com/news/gastroenterology/20231024/video-more-than-75-of-uc-patients-achieve-clinical-response-at-24-weeks-with-tremfya https://www.healio.com/news/gastroenterology/20231025/video-future-is-now-here-for-recurrent-c-difficile-thanks-to-live-biotherapeutics https://www.healio.com/news/gastroenterology/20231025/sensitivity-of-nextgeneration-cologuard-in-precancer-detection-numerically-exceeded-fit Disclosures: Feuerstadt reports financial relationships with Ferring Pharmaceuticals, Regeneron Pharmaceuticals, Seres Therapeutics and Takeda Pharmaceuticals. Imperiale reports grant and research support from Exact Sciences. Loftus reports financial relationships with AbbVie, Alvotech, Amgen, Arena, Avalo Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Exact Sciences, Fresenius Kabi, Genentech, Gilead, GlaxoSmithKline, Gossamer Bio, Iota Biosciences, Iterative Scopes, Janssen, KSL Diagnostics, Lilly, Morphic, Ono Pharma, Pfizer, Protagonist, Receptos, Robarts Clinical Trials, Scipher Medicine, Sun Pharma, Surrozen, Takeda, Theravance and UCB. Wehkamp reports no relevant financial disclosures.

In this episode of Meeting Mic, we bring you Healio's top headlines from DDW 2023. Jessica R. Allegretti, MD, MPH, reviews the results of a Tremfya study presented at the meeting. :09 Ken Blount, PhD, discusses restoration of gut microbiota and clonal engraftment after treatment with Rebyota. 4:07 Evan S. Dellon, MD, MPH, explains the improvements of mepolizumab seen in patients with eosinophilic esophagitis. 10:50 Jessica R. Allegretti also discusses the treatment with Rebyota in patients with inflammatory bowel disease and recurrent Clostridioides difficile infection. 15:16 Shrujal Baxi, MD, MPH, describes the use of artificial intelligence for polyp detection for colorectal cancer. 19:26 Paul Limburg, MD, MPH, AGAF, reviews the revised guidelines and the push for non-invasive screening methods for colorectal cancer. 24:07 Read the full coverage here: https://www.healio.com/news/gastroenterology/20230509/video-patients-with-uc-achieve-symptomatic-remission-as-early-as-week-4-with-tremfya https://www.healio.com/news/gastroenterology/20230509/video-distinctive-shift-in-gut-microbiota-after-rebyota-treatment-for-c-difficile https://www.healio.com/news/gastroenterology/20230510/video-mepolizumab-for-eoe-does-not-yield-prominent-symptom-improvement-after-6-months https://www.healio.com/news/gastroenterology/20230509/video-no-change-in-concomitant-medications-after-rebyota-for-recurrent-c-difficile-ibd

In this episode of Meeting Mic, we bring you expert insights from the ASH Annual Meeting and Exhibition. Mikkael A. Sekeres, MD, MS, chief of the division of hematology and professor of medicine at Sylvester Comprehensive Cancer Center and University of Miami Health System and chair of the ASH committee on communications, discusses some key take-home points from the Long COVID presentation. :00 Shakira J. Grant, MBBS, discusses multilevel interventions required to increase the rate at which Black individuals participate in hematology research studies. 3:44 Arushi Khurana, MBBS, reviews criteria used to disqualify patients from participating in front-line clinical trials, the acceptable ranges of which often prohibited Black and Hispanic patients from enrollment. 6:35 Tatyana Feldman, MD, discusses how the addition of brentuximab vedotin and nivolumab to doxorubicin and dacarbazine appeared active among patients with advanced-stage classical Hodgkin lymphoma. 9:32 Warren B. Fingrut, MD, reviews how hematopoietic stem cell transplant recipients of non-European ancestry had a significantly higher likelihood of receiving allogeneic grafts from HLA-mismatched donors than individuals of European ancestry. 12:02 Read the full coverage here: Restrictive diet an 'unnecessary burden' for patients undergoing HSCT Multilevel interventions needed to reduce racial disparities in clinical trial enrollment Eligibility criteria more likely to exclude minorities from lymphoma clinical trials Combination 'promising' for advanced classical Hodgkin lymphoma Non-European HSCT recipients undergo more complex procedures with fewer resources Disclosures: Feldman reports consulting/advisory roles with, speakers bureau roles with or other financial relationships with AbbVie, ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Genmab, Genomic Testing Cooperative, Janssen, Karyopharm Therapeutics, Kite Pharma, MorphoSys, Pharmacyclics, Secura Bio, Seagen and Takeda. Please see the abstract for all other researchers' relevant financial disclosures. Fingrut reports no relevant financial disclosures. Please see the abstract for all other researchers' relevant financial disclosures. Grant reports no relevant financial disclosures. Please see the abstract for all other researchers' relevant financial disclosures. Khurana reports no relevant financial disclosures.

In this episode of Meeting Mic, we bring you the highlights and insights from the ACR Convergence 2022, as well as Healio's top headlines from the meeting. Virginia G. Kaklamani, MD, DSc, professor of medicine in the division of hematology/oncology at UT Health San Antonio and leader of the breast cancer program at UT Health San Antonio MD Anderson Cancer Center, reviews an abstract presentation on the impact of cyclin-dependent kinase 4/6 inhibitor therapy in patients with advanced breast cancer :00 Aditya Bardia, MD, MPH, director of the breast cancer research program at Massachusetts General Hospital and associate professor of medicine at Harvard Medical School, discusses a study on trastuzumab-deruxtecan and its response rate in patients with early breast cancer 5:00 Sara A. Hurvitz, MD, FACP, medical oncologist at UCLA Health, Santa Monica Medical Center, associate professor at David Geffen School of Medicine at UCLA, medical director of the Jonsson Comprehensive Cancer Center Clinical Research Unit, and director of the breast cancer clinical trials program at UCLA, examines trastuzumab-deruxtecan's effect on patients with breast cancer who were previously treated with trastuzumab and a taxane. 10:00 Read the full coverage here: Longer CDK 4/6 inhibitor therapy enhances elacestrant benefit in metastatic breast cancer Elacestrant extends PFS among certain women with metastatic breast cancer Trastuzumab deruxtecan 'new gold standard' in second line for breast cancer subset Ribociclib regimen may be superior to chemotherapy in advanced breast cancer Breast cancer specialist receives lecture award Genomic assay may predict ovarian function suppression benefit in breast cancer subset Disclosures: Bardia reports research funding from or consultant/advisory roles with AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Immunomedics/Gilead Sciences, Merck, Novartis, Pfizer, Radius Health and Sanofi. Hurvitz reports honoraria from Daichi Sankyo and research funding to her institution from Ambrx, Amgen, Arvinas, AstraZeneca, Bayer, CytomX Therapeutics, Daiichi Sankyo, Dantari, Dignitana, Eli Lilly, G1 Therapeutics, Genentech/Roche, Gilead Sciences, GlaxoSmithKline, Immunomedics, MacroGenics, Novartis, OBI Pharma, Orinoco Pharmaceuticals, Pfizer, Phoenix Molecular Designs, Pieris Pharmaceuticals, Puma Biotechnology, Radius Health, Samumed, Sanofi, Seagen and Zymeworks. She also reports her spouse is a shareholder/stockholder in Ideal Implant. Kaklamani reports honoraria from, consultant/advisory roles with, speakers bureau roles with or other relationships with AstraZeneca, Daiichi Sankyo, Genentech, Genomic Health, Gilead Sciences, Novartis, Pfizer and Puma Biotechnology. Please see the abstract for all other researchers' relevant financial disclosures.

In this episode of Meeting Mic, we bring you the highlights and insights from the ACR Convergence 2022, as well as Healio's top headlines from the meeting. Alfred Kim, MD, discusses some key take-home points from the Long COVID presentation :18 Giovanni Adami, MD, reviews the impact of tofacitinib on fracture risk in patients with rheumatoid arthritis and the effect of glucocorticoids on bone density. 3:39 Leonard Calabrese, DO, gives a long-view of the meeting and the sessions he attended. 6:06   Paul Emery, MD, discusses results of a phase 2 study of peresolimab for adults with rheumatoid arthritis. 9:32 Read the full coverage here: https://www.healio.com/news/rheumatology/ 20221112/understanding- of-long-covid-shifting-at- breakneck-speed  https://www.healio.com/news/rheumatology/ 20221122/bonesafe-glucocorticoid- dose-hard-to-find-in- rheumatic-musculoskeletal- diseases https://www.healio.com/news/rheumatology/ 20221121/pd1-agonist-generates-a-bit-of-excitement- in- rheumatoid- arthritis ACR: Varicella vaccine strongly recommended in all immunosuppressed adults 'Anatomy inventory' fosters more inclusive care for transgender, non-binary patients 'Strange times': Prescribing methotrexate legally 'low risk' Post-Roe Disclosures: Adami reports consultant roles with Amgen, BMS, Eli Lilly, Fresenius Kabi, Galapagos, Theramex and UCB. Calabrese reports consultant roles with AstraZeneca and GSK. Emery reports relationships with AbbVie/Abbott, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Galapagos, Gilead, Novartis, Pfizer, Roche and Samsung. Kim reports no relevant financial disclosures.

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2022 ASCO Annual Meeting, as well as Healio's top headlines from the meeting. Stephen M. Ansell, MD, PhD, discusses efforts to identify new upfront treatment regimens to help extend OS in patients with relapsed or refractory classical Hodgkin lymphoma. :25 Lorenzo Cohen, PhD, shares his thought on the impact of acupuncture regimens on xerostomia and patients' quality of life. 5:26 Bradley J. Monk, MD, discusses the results of a study on the use of rucaparib monotherapy among women with advanced ovarian cancer 10:37 Christopher Manz, MD, MSHP, provides an overview of the results of the randomized PROStep trial, which assessed whether remote patient-reported symptoms and passive activity monitoring could improve patient-clinician communication about symptoms and functional status of patients with cancer. 18:09 Luke Maese, DO, discusses the results of the Children's Oncology Group AALL1931 study, its rationale, the potential implications of the findings and the questions that must be addressed in future research. 21:04     Read the full coverage here: https://www.healio.com/news/hematology-oncology/20220603/firstline-brentuximab-vedotin-regimen-extends-os-in-advanced-classical-hodgkin-lymphoma https://www.healio.com/news/hematology-oncology/20220609/acupuncture-benefits-patients-with-radiationinduced-xerostomia https://www.healio.com/news/hematology-oncology/20220606/rucaparib-shows-efficacy-as-firstline-maintenance-therapy-in-ovarian-cancer https://www.healio.com/news/hematology-oncology/20220610/more-work-to-do-in-oncology-to-collect-useful-data-about-symptoms-functional-status https://www.healio.com/news/hematology-oncology/20220611/intramuscular-recombinant-erwinia-asparaginase-active-safe-in-leukemia-lymphoma-subsets Dostarlimab shows efficacy as curative-intent treatment in rectal cancer subset Source: Cercek A, et al. Abstract LBA5. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago. Trastuzumab deruxtecan extends survival in HER2-low metastatic breast cancer Source: Modi S, et al. Abstract LBA3. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago. Disclosures: Ansell reports research funding to his institution from ADC Therapeutics; Affimed Therapeutics, AI Therapeutics, Bristol Myers Squibb, Regeneron, Seagen and Trillium Therapeutics, and honoraria from Research to Practice and WebMD. Cohen reports no relevant financial disclosures. Monk reports relationships with Clovis Oncology, Merck, Roche/Genentech and several other pharmaceutical companies. Manz reports no relevant financial disclosures. Maese reports consultant and speakers bureau roles with Jazz Pharmaceuticals.

In this episode of Meeting Mic, we bring you pearls and perspectives from the American Thoracic Society 2021 International Conference, as well as Healio's top headlines from the virtual meeting. Leonard Bacharier, MD, discusses results of the VOYAGE study of dupilumab in children with asthma :35 Dennis Hwang, MD, shares data from a study that looked at severe obstructive sleep apnea and COVID-19 risk 7:11 Alayna Tackett, PhD, discusses results of her analysis of e-cigarette use and the association with wheeze and shortness of breath, even in young adults who don't smoke 10:25 Michael Wechsler, MD, shares data from the LIBERTY ASTHMA TRAVERSE Extension Study, which assessed long-term maintenance of oral corticosteroid reduction and efficacy with dupilumab in patients with asthma 14:01 Ana Hernandez Cordero, PhD, discusses data from an integrative genomic analysis of potential genetic risk factors for COVID-19 23:15 Read the full coverage here: https://www.healio.com/news/pulmonology/20210519/tezepelumab-reduces-exacerbations-in-broad-population-of-patients-with-severe-asthma https://www.healio.com/news/pulmonology/20210518/multiple-disease-progression-events-less-likely-with-continued-inhaled-treprostinil https://www.healio.com/news/pulmonology/20210517/monoclonal-antibody-cocktail-cut-covid19-hospitalization-death-by-70-in-outpatient-setting https://www.healio.com/news/pulmonology/20210516/fauci-covid19-vaccines-the-bright-light-of-this-extraordinary-challenge Disclosures: Bacharier reports he received speaker fees from AstraZeneca, GlaxoSmithKline, Regeneron and Sanofi; was on the data safety monitoring board for Cystic Fibrosis Foundation and DBV Technologies; and received research support from NIH, Sanofi and Vectura. Hernandez Cortez reports funding from MITACS and Providence Health Center. Hwang reports that efforts for the study were supported by grants from the American Academy of Sleep Medicine Foundation and from internal Kaiser research support. Tackett reports no relevant financial disclosures. The research was supported by the National Heart Lung and Blood Institute from the NIH and the Oklahoma Tobacco Settlement Endowment Trust. Wechsler reports he received consultant fees from AstraZeneca, Amgen, Boehringer Ingelheim, Cohero Health, Equillium, Genentech, GlaxoSmithKline, Novartis, Regeneron, Sanofi, Sentien and Teva.

In this episode, we bring you pearls and perspectives from Hawaiian Eye 2020.    Ashley Brissette, MD, MSc, FRCSC, considers the importance of testing for inflammation and dry eye before performing cataract surgery :17 Ryan Bleeks, of Sun Ophthalmics, shares an update on Cequa - cyclosporine ophthalmic solution 0.09% - for the treatment of dry eye disease 2:45 Jay S. Pepose, MD, PhD, discusses treatment options for varicella zoster 4:04 Jennifer M. Loh, MD, discusses the impact that sharing a meibomian gland image can have in patient treatment 6:04 Brandon Ayres, MD, examines the use of the FDA-approved epi-off corneal cross-linking procedure 7:16 John P. Berdahl, MD, discusses the benefits of compounded medications that are unique to ophthalmology 10:18 Femida Kherani, MD, shares pearls for incorporating dermal fillers and neuromodulators 12:13 Craig N. Piso, PhD, shares pearls for improving ophthalmic technician performance 13:01 Tom Mitro, president and chief operating officer of Aerie Pharmaceuticals, discusses results of the MOST phase 4 trial 14:30 Richard S. Davidson, MD, discusses surgical correction for keratoconus 15:43 Steven D. Vold, MD, discusses the use of Vyzulta -latanoprostene bunod ophthalmic solution 0.024% by Bausch + Lomb 17:00 Thanks for listening 18:45 Disclosures: Ayres reports being a paid consultant to Glaukos. Bleeks is an employee of Sun Ophthalmics. Brissette reports being a paid consultant to Alcon and Zeiss. Loh reports being a paid consultant to Sight Sciences. Mitro is president and COO of Aerie Pharmaceuticals. Vold reports being a paid consultant to Bausch + Lomb. Davidson, Kherani, Pepose and Piso report no relevant financial disclosures.